Elite Pharmaceuticals, Inc.
ELTP
$0.40
$0.000.73%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 140.12M | 122.89M | 105.45M | 84.04M | 70.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 140.12M | 122.89M | 105.45M | 84.04M | 70.00M |
| Cost of Revenue | 68.57M | 58.18M | 46.61M | 43.96M | 39.09M |
| Gross Profit | 71.55M | 64.71M | 58.84M | 40.09M | 30.91M |
| SG&A Expenses | 12.13M | 12.42M | 10.66M | 9.23M | 9.43M |
| Depreciation & Amortization | 1.59M | 1.63M | 1.66M | 1.69M | 1.66M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 88.43M | 79.13M | 66.41M | 62.84M | 57.82M |
| Operating Income | 51.68M | 43.77M | 39.04M | 21.20M | 12.18M |
| Income Before Tax | 55.23M | 23.75M | -1.46M | -52.10K | -17.33M |
| Income Tax Expenses | 11.82M | 9.82M | 9.35M | 4.26M | 655.90K |
| Earnings from Continuing Operations | 43.41 | 13.92 | -10.82 | -4.31 | -17.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.41M | 13.92M | -10.82M | -4.31M | -17.99M |
| EBIT | 51.68M | 43.77M | 39.04M | 21.20M | 12.18M |
| EBITDA | 53.27M | 45.40M | 40.70M | 22.89M | 13.82M |
| EPS Basic | 0.04 | 0.01 | -0.01 | 0.00 | -0.02 |
| Normalized Basic EPS | 0.03 | 0.01 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | 0.02 | 0.00 | -0.01 | 0.00 | -0.02 |
| Normalized Diluted EPS | 0.03 | 0.01 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 4.28B | 4.28B | 4.27B | 4.27B | 4.22B |
| Average Diluted Shares Outstanding | 4.42B | 4.35B | 4.27B | 4.28B | 4.25B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |